Role of nitric oxide in the vasodilator effect of recombinant human growth hormone in patients with dilated cardiomyopathy
- 作者：Osterziel ; Karl Josef ; Bode-Bö ; ger ; Stefanie M. ; Strohm ; Oliver ; Ellmer ; Annette E. ; et. al.
- 关键词：Cardiomyopathy ; Endothelial factors ; Growth factors ; Hemodynamics ; Nitric oxide
- 刊名：Cardiovascular Research
- 出版年：2000
- 期刊代码：48_00086363
- 类别：med
- 出版时间：January 14, 2000
- 卷：45
- 期：2
- 页码：447-453
- 文件大小：106 K
摘要
Objective: Dilated cardiomyopathy is characterized by elevated arterial vascular resistance and impaired nitric oxide (NO)-dependent vasodilation. Insulin-like growth factor-I (IGF-I) has been shown to stimulate endothelial NO-synthase resulting in endothelium-dependent vasodilation. Growth hormone (GH) substitution therapy leads in GH-deficient patients to significant increases of IGF-I which may alter systemic vascular resistance by stimulating NO production. This study was designed to evaluate the effects of treatment with recombinant human growth hormone (GH) on NO production and NO-dependent vascular effects in patients with dilated cardiomyopathy. Methods: 50 patients with dilated cardiomyopathy were randomly assigned to double-blind treatment with 2 I.U. of GH or placebo for 3 months. Central hemodynamics were determined by Swan-Ganz catheter and cardiac output was obtained by the thermodilution method. Serum GH and IGF-I levels were measured and systemic NO production was determined from urinary nitrate and cyclic GMP excretion rates in 42 patients. Results: GH treatment caused in comparison to the placebo group a significant increase of IGF-I by 91 ng/ml (P